Grant: CIHR Fellowship
Direct Payment
$100,000.00
The comparative effectiveness and safety of four second-line antihyperglycemic drugs in type 2 diabetes mellitus: an international multi-centre cohort study
EF 2021-22
Résumé
The treatment landscape for type 2 diabetes mellitus has significantly changed in the last decade with the introduction of several new drug classes. These include dipeptidyl peptidase-4 inhibitors (DPP-4I), glucagon-like peptide-1 receptor agonists (GLP-1RA), and sodium-glucose co-transporter 2 inhibitors (SGLT-2I). These new antihyperglycemic drugs are intended to be used as second- or third-line treatments, along with an older class of drugs called sulfonylureas (SU). While clinical trials of these new medications have established cardiovascular safety, and in some instances (GLP-1RA and SGLT-2I) efficacy, among patients with cardiovascular disease at baseline, there has been limited focus on patients at mild-to-moderate risk for cardiovascular disease. Indeed, while this subgroup of patients represents the majority of patients with type 2 diabetes mellitus, this population has been underrepresented in long-term clinical trials. This leaves patients and physicians with little guidance for selecting the best second-line treatment strategy. Given this gap of knowledge, the objective of this international multi-centre study is to determine which second-line antihyperglycemic drug should be recommended for patients with mild-to-moderate cardiovascular risk. This study will provide patients, physicians, and regulatory agencies with much needed information on the effectiveness and safety of newer antihyperglycemic medications, which may inform prescribing guidelines. Using real-world evidence and multiple databases, this study will provide information in a cost-effective and timely fashion.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
454462
Name
Abrahami Devin
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Health Research Training A - Post-PhD (HTA)
Projecttitle
The comparative effectiveness and safety of four second-line antihyperglycemic drugs in type 2 diabetes mellitus: an international multi-centre cohort study
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cardiovascular Disease; Comparative Safety; Drug Safety; Pharmacoepidemiology; Real World Evidence; Type 2 Diabetes
Abstract
The treatment landscape for type 2 diabetes mellitus has significantly changed in the last decade with the introduction of several new drug classes. These include dipeptidyl peptidase-4 inhibitors (DPP-4I), glucagon-like peptide-1 receptor agonists (GLP-1RA), and sodium-glucose co-transporter 2 inhibitors (SGLT-2I). These new antihyperglycemic drugs are intended to be used as second- or third-line treatments, along with an older class of drugs called sulfonylureas (SU). While clinical trials of these new medications have established cardiovascular safety, and in some instances (GLP-1RA and SGLT-2I) efficacy, among patients with cardiovascular disease at baseline, there has been limited focus on patients at mild-to-moderate risk for cardiovascular disease. Indeed, while this subgroup of patients represents the majority of patients with type 2 diabetes mellitus, this population has been underrepresented in long-term clinical trials. This leaves patients and physicians with little guidance for selecting the best second-line treatment strategy. Given this gap of knowledge, the objective of this international multi-centre study is to determine which second-line antihyperglycemic drug should be recommended for patients with mild-to-moderate cardiovascular risk. This study will provide patients, physicians, and regulatory agencies with much needed information on the effectiveness and safety of newer antihyperglycemic medications, which may inform prescribing guidelines. Using real-world evidence and multiple databases, this study will provide information in a cost-effective and timely fashion.
Competitiondate
202110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Abrahami, Devin
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~